{"id":"cannabidiol-cbd-oil-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Changes in appetite"},{"rate":null,"effect":"Hepatic enzyme elevation"},{"rate":null,"effect":"Drug-drug interactions via CYP3A4/CYP2C19"}]},"_chembl":{"chemblId":"CHEMBL190461","moleculeType":"Small molecule","molecularWeight":"314.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CBD acts as a negative allosteric modulator of CB1 and CB2 receptors, while also interacting with serotonin receptors (5-HT1A), vanilloid receptors (TRPV1), and other targets. This multi-target activity reduces neuroinflammation, modulates immune responses, and may provide neuroprotection without the psychoactive effects associated with THC.","oneSentence":"Cannabidiol modulates endocannabinoid signaling and multiple non-cannabinoid receptors to produce anti-inflammatory, anxiolytic, and neuroprotective effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:02.602Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (seizure disorders)"},{"name":"Anxiety disorders"},{"name":"Chronic pain"},{"name":"Inflammation-related conditions"}]},"trialDetails":[{"nctId":"NCT05942911","phase":"PHASE2","title":"Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Incannex Healthcare Ltd","startDate":"2023-11-22","conditions":"Rheumatoid Arthritis","enrollment":20},{"nctId":"NCT07279558","phase":"PHASE2","title":"Cannabidiol and Alcohol Use Disorder Phenotypes","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-02-01","conditions":"Alcohol Use Disorder","enrollment":180},{"nctId":"NCT07148206","phase":"PHASE3","title":"Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":40},{"nctId":"NCT05632627","phase":"PHASE2","title":"Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2023-04-11","conditions":"Brain Injuries, Traumatic","enrollment":43},{"nctId":"NCT05618756","phase":"NA","title":"CBD, Nutrient Metabolism and Energy Intake","status":"COMPLETED","sponsor":"Loughborough University","startDate":"2021-09-30","conditions":"Glucose Metabolism Disorders (Including Diabetes Mellitus), Lipid Metabolism Disorders, Appetitive Behavior","enrollment":15},{"nctId":"NCT06578455","phase":"PHASE1","title":"A Pharmacokinetic Study to Compare CBD-NE to Epidyolex in Healthy Adult Volunteers Under Both Fed and Fasted Conditions","status":"COMPLETED","sponsor":"dsm-firmenich Switzerland AG","startDate":"2024-08-30","conditions":"CBD Pharmacokinetics, Healthy Participants","enrollment":32},{"nctId":"NCT06514066","phase":"PHASE2, PHASE3","title":"Cannabidiol's Role in Dementia Management","status":"NOT_YET_RECRUITING","sponsor":"Hospital Pengajar Universiti Putra Malaysia","startDate":"2024-09-01","conditions":"Dementia, Vascular, Dementia, Mixed","enrollment":486},{"nctId":"NCT03877991","phase":"EARLY_PHASE1","title":"Bioequivalence Assessment of Cannabidiol (CBD) Administrated in Oral Formulations","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2024-02-19","conditions":"Pain","enrollment":12},{"nctId":"NCT04911127","phase":"PHASE1","title":"Therapeutic Response of Cannabidiol in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2021-10-05","conditions":"Rheumatoid Arthritis, Cannabis","enrollment":67},{"nctId":"NCT03549819","phase":"PHASE3","title":"Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2021-12-15","conditions":"Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder","enrollment":50},{"nctId":"NCT04808531","phase":"PHASE3","title":"NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers","status":"UNKNOWN","sponsor":"Medlab Clinical","startDate":"2023-11","conditions":"Cancer Related Pain","enrollment":360},{"nctId":"NCT05108220","phase":"","title":"Evaluation of Effects of CBD Products on Anxiety Among U.S. Women","status":"COMPLETED","sponsor":"Radicle Science","startDate":"2020-10-15","conditions":"Anxiety, Generalized Anxiety Disorder","enrollment":1350},{"nctId":"NCT03808935","phase":"PHASE3","title":"Cannabis Extract in Refractory Epilepsy Study","status":"TERMINATED","sponsor":"The Epilepsy Research Program of the Ontario Brain Institute","startDate":"2019-01-10","conditions":"Drug Resistant Epilepsy","enrollment":17},{"nctId":"NCT03763851","phase":"PHASE2","title":"Cannabis Oil and Radiation Therapy for the Management of Pain","status":"TERMINATED","sponsor":"Tetra Bio-Pharma","startDate":"2018-03-14","conditions":"Metastatic Prostate Cancer, Lung Cancer, Breast Cancer","enrollment":100},{"nctId":"NCT03295903","phase":"EARLY_PHASE1","title":"Cannabinoid Supplementation on Vascular and Cognitive Function","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2018-01-01","conditions":"Diet Modification","enrollment":24},{"nctId":"NCT03635593","phase":"PHASE2","title":"Cannabis Oil for Chronic Non-Cancer Pain Treatment","status":"UNKNOWN","sponsor":"Hamilton Health Sciences Corporation","startDate":"2019-01-01","conditions":"Chronic Non-cancer Pain","enrollment":309}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cannabidiol (CBD) Oil Capsules","genericName":"Cannabidiol (CBD) Oil Capsules","companyName":"McMaster University","companyId":"mcmaster-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cannabidiol modulates endocannabinoid signaling and multiple non-cannabinoid receptors to produce anti-inflammatory, anxiolytic, and neuroprotective effects. Used for Epilepsy (seizure disorders), Anxiety disorders, Chronic pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}